How many stocks are there of Mesoblast?
The current number of stocks of Mesoblast is 1.21 B undefined.
Mesoblast Stocks 2025
Mesoblast Stocks
1.21 B
Ticker
MSB.AX
ISIN
AU000000MSB8
WKN
A0DNPW
In 2025, Mesoblast had 1.21 B outstanding stocks, a 22.41% change from the 986.7 M stocks in the previous year.
The Mesoblast Stocks history
| YEAR | NUMBER OF STOCKS (B USD) |
|---|---|
| 2031e | 1.21 |
| 2030e | 1.21 |
| 2029e | 1.21 |
| 2028e | 1.21 |
| 2027e | 1.21 |
| 2026e | 1.21 |
| 2025 | 1.21 |
| 2024 | 0.99 |
| 2023 | 0.78 |
| 2022 | 0.68 |
| 2021 | 0.64 |
| 2020 | 0.53 |
| 2019 | 0.49 |
| 2018 | 0.47 |
| 2017 | 0.4 |
| 2016 | 0.36 |
| 2015 | 0.32 |
| 2014 | 0.32 |
| 2013 | 0.3 |
| 2012 | 0.29 |
| 2011 | 0.23 |
| 2010 | 0.14 |
| 2009 | 0.13 |
| 2008 | 0.12 |
| 2007 | 0.11 |
| 2006 | 0.09 |
Mesoblast shares outstanding
The number of shares was Mesoblast in 2024 — This indicates how many shares 986.703 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Number of stocks
Details
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Mesoblast earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Mesoblast's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Mesoblast’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mesoblast's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Mesoblast Aktienanalyse
What does Mesoblast do?
Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Mesoblast's Shares Outstanding
Mesoblast's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Mesoblast’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Mesoblast’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Mesoblast’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Mesoblast stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Mesoblast are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Mesoblast evolved in recent years?
The number of shares of Mesoblast has increased by 22.41% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Mesoblast as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Mesoblast?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Mesoblast pay?
Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.
What is the dividend yield of Mesoblast?
The current dividend yield of Mesoblast is .
When does Mesoblast pay dividends?
Mesoblast pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mesoblast?
Mesoblast paid dividends every year for the past 0 years.
What is the dividend of Mesoblast?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mesoblast located?
Mesoblast is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mesoblast from 10/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2025.
When did Mesoblast pay the last dividend?
The last dividend was paid out on 10/5/2025.
What was the dividend of Mesoblast in the year 2024?
In the year 2024, Mesoblast distributed 0 USD as dividends.
In which currency does Mesoblast pay out the dividend?
The dividends of Mesoblast are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mesoblast
Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
